专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2018175319A1 HEAVY CHAIN ONLY ANTIBODIES TO VEGF 审中-公开
公开(公告)号：WO2018175319A1
公开(公告)日：2018-09-27
申请号：PCT/US2018/023141
申请日：2018-03-19
申请人： ALLERGAN, INC.
发明人： LIANG, Yanbin , GIL, Daniel
IPC分类号： A61K39/395 , C07K16/22 , C07K16/28
摘要： Disclosed herein are monospecific HCAb antibodies with specificity for VEGF, bispecific antibodies with specificities for VEGF-A and PDGF or for VEGF-A and ANG-2, or trispecific antibodies with specificities for VEGF, PDGF, and ANG-2. Methods for using the antibodies are also disclosed.

2. 发明申请

WO2005035713A2 HUMAN COX-1 ALTERNATIVELY SPLICED VARIANTS AND METHODS OF USING SAME 审中-公开
标题翻译：人类COX-1替代性变异体及其使用方法
公开(公告)号：WO2005035713A2
公开(公告)日：2005-04-21
申请号：PCT/US2004/027105
申请日：2004-08-20
申请人： ALLERGAN, INC. , LIANG, Yanbin , WOODWARD, David, F.
发明人： LIANG, Yanbin , WOODWARD, David, F.
IPC分类号： C12N
CPC分类号： C12N9/0083
摘要： The invention provides an isolated polypeptide containing the amino acid sequence of SEQ ID NO: 14, 16, 18, 20, 22 or 24. The invention also provides an isolated polypeptide containing a) an amino acid sequence having at least 50% amino acid identity with SEQ ID NO: 10, and b) an amino acid sequence selected from SEQ ID NOS: 14, 16, 18, 20, 22, or 24; or a conservative variant thereof. The invention further provides an isolated polypeptide containing the amino acid sequence of SEQ ID NO: 2, 4, 6, or 8. The invention also provides a method for identifying a compound that modulates a COX-1 variant by contacting an isolated COX-1 variant or a COX-1 variant over-expressed in, a genetically engineered cell with a compound and determining the level of an indicator which correlates with modulation of a COX-1 variant, where an alteration in the level of the indicator as compared to a control level indicates that the compound is a compound that modulates the COX-1 variant.
摘要翻译：本发明提供了含有SEQ ID NO：14,16,18,20,22或24的氨基酸序列的分离的多肽。本发明还提供了分离的多肽，其含有a）具有至少50％氨基酸同一性的氨基酸序列具有SEQ ID NO：10，和b）选自SEQ ID NO：14,16,18,20,22或24的氨基酸序列; 或其保守变体。本发明还提供了含有SEQ ID NO：2,4,6或8的氨基酸序列的分离的多肽。本发明还提供了通过使分离的COX-1接触来鉴定调节COX-1变体的化合物的方法变体或在具有化合物的基因工程细胞中过表达的COX-1变体，并确定与COX-1变体的调节相关的指示剂的水平，其中指示剂水平的变化与对照水平表明该化合物是调节COX-1变体的化合物。

3. 发明申请

WO2002094775A3 RECOMBINANT SIMIAN GPR3 RECEPTOR 审中-公开
公开(公告)号：WO2002094775A3
公开(公告)日：2002-11-28
申请号：PCT/US2002/014917
申请日：2002-05-10
申请人： ALLERGAN, INC.
发明人： LIANG, Yanbin , WOODWARD, David, F. , LI, Chen
IPC分类号： C07H21/02
摘要： The invention provides recombinant materials for the production of the simian form of G-protein receptor 3 which differs in several aspects from the human counterpart. Compounds which interact with this receptor are useful in the treatment of glaucoma.

4. 发明申请

WO2017020001A2 HEAVY CHAIN ONLY ANTIBODIES TO ANG-2 审中-公开
标题翻译： ANG-2的重链抗体
公开(公告)号：WO2017020001A2
公开(公告)日：2017-02-02
申请号：PCT/US2016/044838
申请日：2016-07-29
申请人： ALLERGAN, INC.
发明人： LIANG, Yanbin , GIL, Daniel W.
IPC分类号： C07K16/22
CPC分类号： C07K16/22 , C07K2317/24 , C07K2317/33 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/64 , C07K2317/76 , C07K2317/92
摘要： Disclosed herein are monospecific HCAb antibodies with antigen-binding specificity to ANG-2 and bispecific antibodies with antigen-binding specificities to ANG-2 and VEGF or PDGF.
摘要翻译：本文公开了对ANG-2具有抗原结合特异性的单特异性HCAb抗体和对ANG-2和VEGF或PDGF具有抗原结合特异性的双特异性抗体。

5. 发明申请

WO2015130826A1 COMPLEMENT FACTOR Bb ANTIBODIES 审中-公开
标题翻译：补充因子Bb抗体
公开(公告)号：WO2015130826A1
公开(公告)日：2015-09-03
申请号：PCT/US2015/017578
申请日：2015-02-25
申请人： ALLERGAN, INC.
发明人： LIANG, Yanbin , LI, Chen , LEE, Iris , GUZMAN, Victor M.
IPC分类号： C07K16/18 , C07K16/36
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/24
摘要： The present disclosure relates to antibodies and polynucleotides encoding the same, which may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement Factor Bb. Specifically, the disclosure is related to anti-complement Factor Bb antibodies.
摘要翻译：本公开涉及编码该抗体和多核苷酸的抗体和多核苷酸，其可用于预防，控制或降低补体途径的活性。此外，本公开涉及用于诊断和治疗由补体因子Bb介导或涉及补体因子Bb的疾病的组合物和方法。具体地，本公开涉及抗补体因子Bb抗体。

6. 发明申请

WO2002094775A2 RECOMBINANT SIMIAN GPR3 RECEPTOR 审中-公开
标题翻译：重组SIMIAN GPR3受体
公开(公告)号：WO2002094775A2
公开(公告)日：2002-11-28
申请号：PCT/US2002/014917
申请日：2002-05-10
申请人： ALLERGAN, INC.
发明人： LIANG, Yanbin , WOODWARD, David, F. , LI, Chen
IPC分类号： C07D
CPC分类号： C07K14/705 , A61K38/00
摘要： The invention provides recombinant materials for the production of the simian form of G-protein receptor 3 which differs in several aspects from the human counterpart. Compounds which interact with this receptor are useful in the treatment of glaucoma.
摘要翻译：本发明提供用于生产猿猴形式的G蛋白受体3的重组材料，其在几个方面与人对应物不同。与该受体相互作用的化合物可用于治疗青光眼。

7. 发明申请

WO2017030909A1 HEAVY CHAIN ONLY ANTIBODIES TO PDGF 审中-公开
标题翻译：重链仅PDGF抗体
公开(公告)号：WO2017030909A1
公开(公告)日：2017-02-23
申请号：PCT/US2016/046595
申请日：2016-08-11
申请人： ALLERGAN, INC.
发明人： LIANG, Yanbin , GIL, Daniel W.
IPC分类号： C07K16/22
CPC分类号： C07K16/22 , C07K2317/24 , C07K2317/52 , C07K2317/522 , C07K2317/565 , C07K2317/569 , C07K2317/64 , C07K2317/76 , C07K2317/92
摘要： Disclosed herein are monospecific HCAb antibodies with antigen-binding specificity to PDGF and bispecific antibodies with antigen-binding specificities to PDGF-2 and VEGF or to PDGF and ANG-2.
摘要翻译：本文公开了具有与PDGF的抗原结合特异性和对PDGF-2和VEGF或PDGF和ANG-2具有抗原结合特异性的双特异性抗体的单特异性HCAb抗体。

8. 发明申请

WO2005113597A1 HUMAN CXCR3 RECEPTOR VARIANTS AND METHODS OF USE 审中-公开
标题翻译：人CXCR3受体变异体及其使用方法
公开(公告)号：WO2005113597A1
公开(公告)日：2005-12-01
申请号：PCT/US2005/017636
申请日：2005-05-18
申请人： ALLERGAN, INC. , LIANG, Yanbin , WOODWARD, David, F.
发明人： LIANG, Yanbin , WOODWARD, David, F.
IPC分类号： C07K14/715
CPC分类号： C07K14/7158
摘要： The present invention provides alternatively spliced CXCR3 variants, as well as related nucleic acid molecules and screening methods.
摘要翻译：本发明提供可选剪接的CXCR3变体，以及相关的核酸分子和筛选方法。

9. 发明申请

WO2005046577A2 HUMAN PROSTAGLANDIN EP1 RECEPTOR VARIANTS AND METHODS OF USING SAME 审中-公开
标题翻译：人类PROSTAGLANDIN EP1受体变异体及其使用方法
公开(公告)号：WO2005046577A2
公开(公告)日：2005-05-26
申请号：PCT/US2004/027782
申请日：2004-08-26
申请人： ALLERGAN, INC. , LIANG, Yanbin , WOODWARD, David, F.
发明人： LIANG, Yanbin , WOODWARD, David, F.
IPC分类号： A61K
CPC分类号： C07K14/72
摘要： The present invention relates to nucleic acid molecules encoding novel, alternatively spliced EP 1 receptor variants. Variant EP 1 polypeptides and screening methods based on such polypeptides also are provided.
摘要翻译：本发明涉及编码新的，可选择剪接的EP1受体变体的核酸分子。还提供了变体EP1多肽和基于这些多肽的筛选方法。

10. 发明申请

WO2005007688A2 HUMAN PROSTAGLANDIN FP RECEPTOR VARIANTS AND METHODS OF USING SAME 审中-公开
标题翻译：人类PROSTAGLANDIN FP受体变异体及其使用方法
公开(公告)号：WO2005007688A2
公开(公告)日：2005-01-27
申请号：PCT/US2004/022585
申请日：2004-07-12
申请人： ALLERGAN, INC. , LIANG, Yanbin , WOODWARD, David, F.
发明人： LIANG, Yanbin , WOODWARD, David, F.
IPC分类号： C07K14/00
CPC分类号： G01N33/88 , C07K14/72 , G01N2500/04
摘要： The invention provides an isolated polypeptide containing the amino acid sequence of SEQ ID NO: 17, 18, 19, 20, 21, 22, 23, 24, or 25. The invention also provides an isolated polypeptide containing an amino acid sequence having at least 50% amino acid identity with SEQ ID NO: 14 and an amino acid sequence of SEQ ID NO: 17, 18, 19, 20, 21, 22, 23, 24, or 25, or a conservative variant thereof. The invention further provides an isolated polypeptide containing the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 10, or 12. The invention also provides a method for identifying a compound that modulates a FP receptor variant by contacting an isolated FP receptor variant or a FP receptor variant over-expressed in a genetically engineered cell with a compound and determining the level of an indicator which correlates with modulation-of a FP receptor variant, where an alteration in the level of the indicator as compared to a control level indicates that the compound is a compound that modulates the FP receptor variant.
摘要翻译：本发明提供了含有SEQ ID NO：17,18,19,20,21,22,23,24或25的氨基酸序列的分离的多肽。本发明还提供了一种分离的多肽，其含有至少具有至少与SEQ ID NO：14的50％氨基酸同一性和SEQ ID NO：17,18,19,20,21,22,23,24或25的氨基酸序列或其保守变体。本发明还提供了含有SEQ ID NO：2,4,6,8,10或12的氨基酸序列的分离的多肽。本发明还提供了一种鉴定通过使分离的 FP受体变体或在具有化合物的遗传工程改造的细胞中过表达的FP受体变体，并确定与FP受体变体的调节相关的指标水平，其中指示剂水平的变化与对照水平表明该化合物是调节FP受体变体的化合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式